BIO vs EDIT · rev $2.58B vs rev $32.3M
BIO (BIO) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
BIO currently screens at market cap $0. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the BIO and EDIT stock pages for the full models.
Not investment advice.